Castle Biosciences Analyst Price Targets

Castle Biosciences Inc

CSTLNASDAQ

Trade with Public

$31.96

-1.84-5.44%

最終更新: Oct 16, 4:00 PM

$31.96

-1.84-5.44%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Castle Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Castle Biosciences (CSTL).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$42Upside to Avg. PT+32.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 3, 2026	BTIG	Mark Massaro	PT Raise	Buy	$40→$44
Jun 25, 2026	Roth Capital	Max Masucci	Initiate	Buy	$40
May 13, 2026	BTIG	Mark Massaro	PT Cut	Buy	$50→$40
May 7, 2026	Baird	Catherine Ramsey	PT Cut	Outperform	$44→$43
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$50→$40
Feb 27, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$41→$44
Jan 26, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$43→$47
Jan 12, 2026	Lake Street	Thomas Flaten	PT Raise	Buy	$35→$52
Jan 5, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$30→$43
Dec 22, 2025	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$37→$50
Dec 12, 2025	BTIG	Mark Massaro	PT Raise	Buy	$38→$50
Nov 5, 2025	BTIG	Mark Massaro	PT Raise	Buy	$32→$38
Nov 4, 2025	Baird	Catherine Ramsey	PT Raise	Outperform	$39→$41
Sep 9, 2025	Canaccord Genuity	Kyle Mikson	Maintained	Buy	$37
May 21, 2025	Scotiabank	Sung Ji Nam	PT Cut	Sector Outperform	$44→$40
May 6, 2025	Lake Street	Thomas Flaten	PT Cut	Buy	$40→$35
May 6, 2025	Canaccord Genuity	Kyle Mikson	PT Cut	Buy	$42→$37
Feb 28, 2025	Baird	Catherine Ramsey	PT Raise	Outperform	$36→$37
Jan 2, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$41
Nov 6, 2024	Scotiabank	Sung Ji Nam	PT Raise	Sector Outperform	$37→$44

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $40 to $44.

Benzinga Newsdesk

This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades & initiations on analyst ratings page.

Avi Kapoor

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratings page for complete view.

Avi Kapoor

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP stock may be worth considering, analysts say.

Avi Kapoor

PRO
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

Roth Capital analyst Max Masucci initiates coverage on Castle Biosciences (NASDAQ:CSTL) with a Buy rating and announces Price Target of $40.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $50 to $40.

Benzinga Newsdesk

Castle Biosciences Inc

Castle Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

PRO
BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

ニュース

パートナーシップ

ベンジンガ・グローバル

Castle Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRO
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

PRO
BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

People Also Watch

People Also Watch

Castle Biosciences Inc

Castle Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRORoth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

PROBTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

ニュース

パートナーシップ

ベンジンガ・グローバル

Castle Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday

This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

PRORoth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

PROBTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

People Also Watch

People Also Watch

PRO
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

PRO
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

PRO
BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

PRO
BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

PRO
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40

PRO
BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40